- $662.30m
- $251.53m
Brief: Olema Pharmaceuticals Inc - Confirms That It Does Not Hold Cash Deposits Or Securities At Silicon Valley Bank
Brief: Olema Pharmaceuticals Inc Files For Common Stock Offering Of Up To $100 Million - SEC Filing
Olema Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Olema Oncology Reports Fourth Quarter And Full-Year 2022 Financial Results
Olema Pharmaceuticals Inc expected to post a loss of 65 cents a share - Earnings Preview
Olema Pharmaceuticals Inc expected to post a loss of 65 cents a share - Earnings Preview
Brief: Olema Oncology Reports Third Quarter 2022 Financial Results
Brief: Olema Oncology Says OP-1250 Continues To Demonstrate Robust Activity In Phase 1/2 Clinical Trial
Arvinas slides after Sanofi scraps breast cancer drug
Olema Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Olema Oncology Advances Op-1250 Into Phase 2 Monotherapy Expansion In Patients With Er+/Her2- Advanced Breast Cancer
Brief: Olema Pharmaceuticals QTRLY Net Loss Per Share $0.82
U.S. STOCKS ON THE MOVE-Rivian, One Medical, Evofem Biosciences
U.S. STOCKS ON THE MOVE-Philip Morris, AT&T, Olema Pharmaceuticals
Olema surges on FDA's 'fast track' tag for breast cancer therapy
Brief: Olema Oncology Receives FDA Fast Track Designation For OP-1250 For The Treatment Of ER+ / HER2- Metastatic Breast Cancer
U.S. STOCKS ON THE MOVE-Novavax, Signet Jewelers, Zendesk, Roblox
U.S. STOCKS ON THE MOVE-Tesla, Roblox, Novavax, Couchbase
Brief: Olema Oncology Provides Clinical Update Reflecting Strong Progress Across Op-1250 Development Program